UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MP14-11 SINGLE CELL-BASED IMMUNE PROFILING OF THE TUMOR AND ITS IMMUNE MICROENVIRONMENT REVEALED DIFFERENCES BETWEEN NMIBC AND MIBC: IMPLICATION FOR IMMUNO-THERAPY

The Journal of urology, 2023-04, Vol.209 (Supplement 4)

2023

Volltextzugriff (PDF)

MP71-12 EVALUATING THE OUTCOMES OF BLADDER-SPARING TREATMENTS (BST) IN PATIENTS WITH BCG-UNRESPONSIVE AND BCG-EXPOSED NMIBC

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2021-07, Vol.206 (1), p.27-27

2021

Volltextzugriff (PDF)

Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience

World journal of urology, 2021-10, Vol.39 (10), p.3867-3873

2021

Volltextzugriff (PDF)

When and How To Perform Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer

European urology focus, 2023-07, Vol.9 (4), p.564-566

2023

Volltextzugriff (PDF)

MicroRNA-30c-5p modulates neuropathic pain in rodents

Science translational medicine, 2018-08, Vol.10 (453)

2018

Volltextzugriff (PDF)

MP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance

The Journal of urology, 2023-11, Vol.210 (5), p.763-770

2023

Volltextzugriff (PDF)

Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis

Cancer treatment and research communications, 2021, Vol.27, p.100369-100369, Article 100369

2021

Volltextzugriff (PDF)

MP35-10 LONG TERM FOLLOW UP AND RISK OF HIGH-GRADE RECURRENCE IN LOW-GRADE PTA BLADDER CANCER PATIENTS

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

PD30-07 HIGH-GRADE TA NON-MUSCLE INVASIVE BLADDER CANCER DEMONSTRATES HOMOGENEOUS ONCOLOGICAL OUTCOMES REGARDLESS OF EAU 2021 RISK GROUP STRATIFICATION

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

MP16-01 REPLACING RETUR WITH CYSTOSCOPY IN HIGH-GRADE T1 NMIBC PATIENTS: CONFIRMATORY RESULTS FROM THE HUNIRE TRIAL

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Assessing long‐term upgrade risks in recurrent low‐grade non‐muscle‐invasive bladder cancer, can we deintensify the treatment?

BJU international, 2024-08, Vol.134 (2), p.195-197

2024

Volltextzugriff (PDF)

Reply by Authors

The Journal of urology, 2023-11, Vol.210 (5), p.770-770

2023

Volltextzugriff (PDF)

Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study

Frontiers in oncology, 2022-01, Vol.12, p.832835-832835

2022

Volltextzugriff (PDF)

Inflammatory markers and Type 2 diabetes mellitus as prognostic risk factors in low‐risk bladder cancer

BJU international, 2023-08, Vol.132 (2), p.154-156

2023

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2021-07, Vol.206 (1), p.27-27

2021

Volltextzugriff (PDF)

MP22-13 FRAILTY ADAPTED ERAS PATHWAY FOR PATIENTS WITH BLADDER CANCER REQUIRING SURGERY: THE GLOBAL RADICAL CYSTECTOMY EVALUATION AND MANAGEMENT (GRACEM) STUDY PROTOCOL

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy

Future science OA, 2021-08, Vol.7 (7)

2021

Volltextzugriff (PDF)

Imaging predictive biomarkers of response in patients with prostate cancer undergoing high-intensity focused ultrasound (HIFU) focal therapy

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.288-288

2024

Volltextzugriff (PDF)

Identification of Epigenetic Interactions between MicroRNA-30c-5p and DNA Methyltransferases in Neuropathic Pain

International journal of molecular sciences, 2022-11, Vol.23 (22), p.13994

2022

Volltextzugriff (PDF)

Editorial Comment

The Journal of urology, 2021-04, p.101097JU000000000000168901

2021

Volltextzugriff (PDF)

MP23-19 PROSPECTIVE VALIDATION OF THE ROL SYSTEM IN SUBSTAGING PT1 HIGH-GRADE BLADDER CANCER: A CONFIRMATORY PROGRESSION RISK ANALYSIS TO EASE DECISION MAKING

The Journal of urology, 2022-05, Vol.207 (Supplement 5)

2022

Volltextzugriff (PDF)

Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer

Frontiers in oncology, 2022-09, Vol.12, p.968384-968384

2022

Volltextzugriff (PDF)

Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence

Therapeutic Advances in Urology, 2016-04, Vol.8 (2), p.91-99

2016

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(107)

Sprache

Englisch
(107)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(41)
Science & Technology
(41)
Urology & Nephrology
(26)
Humans
(18)
Bladder Cancer
(17)
Urology
(15)
Oncology
(13)
Male
(12)
Prostate Cancer
(10)
Patients
(9)
Urinary Bladder Neoplasms - Pathology
(8)
Aged
(7)
Female
(7)
Urinary Bladder - Pathology
(6)
Watchful Waiting
(6)
Active Surveillance
(5)
Biopsy
(5)
Medicine
(5)
Medicine & Public Health
(5)
Non-Muscle Invasive Bladder Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

MP14-11 SINGLE CELL-BASED IMMUNE PROFILING OF THE TUMOR AND ITS IMMUNE MICROENVIRONMENT REVEALED DIFFERENCES BETWEEN NMIBC AND MIBC: IMPLICATION FOR IMMUNO-THERAPY

MP71-12 EVALUATING THE OUTCOMES OF BLADDER-SPARING TREATMENTS (BST) IN PATIENTS WITH BCG-UNRESPONSIVE AND BCG-EXPOSED NMIBC

Editorial Comment

Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience

When and How To Perform Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer

MicroRNA-30c-5p modulates neuropathic pain in rodents

MP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE

International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance

Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis

MP35-10 LONG TERM FOLLOW UP AND RISK OF HIGH-GRADE RECURRENCE IN LOW-GRADE PTA BLADDER CANCER PATIENTS

PD30-07 HIGH-GRADE TA NON-MUSCLE INVASIVE BLADDER CANCER DEMONSTRATES HOMOGENEOUS ONCOLOGICAL OUTCOMES REGARDLESS OF EAU 2021 RISK GROUP STRATIFICATION

MP16-01 REPLACING RETUR WITH CYSTOSCOPY IN HIGH-GRADE T1 NMIBC PATIENTS: CONFIRMATORY RESULTS FROM THE HUNIRE TRIAL

Assessing long‐term upgrade risks in recurrent low‐grade non‐muscle‐invasive bladder cancer, can we deintensify the treatment?

Reply by Authors

Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study

Inflammatory markers and Type 2 diabetes mellitus as prognostic risk factors in low‐risk bladder cancer

Editorial Comment

MP22-13 FRAILTY ADAPTED ERAS PATHWAY FOR PATIENTS WITH BLADDER CANCER REQUIRING SURGERY: THE GLOBAL RADICAL CYSTECTOMY EVALUATION AND MANAGEMENT (GRACEM) STUDY PROTOCOL

Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy

Imaging predictive biomarkers of response in patients with prostate cancer undergoing high-intensity focused ultrasound (HIFU) focal therapy

Identification of Epigenetic Interactions between MicroRNA-30c-5p and DNA Methyltransferases in Neuropathic Pain

Editorial Comment

MP23-19 PROSPECTIVE VALIDATION OF THE ROL SYSTEM IN SUBSTAGING PT1 HIGH-GRADE BLADDER CANCER: A CONFIRMATORY PROGRESSION RISK ANALYSIS TO EASE DECISION MAKING

Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer

Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence

Suchergebnisse filtern